COMPANY OVERVIEW

TransThera Biosciences, founded in 2016, is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs, including cancer, cardiovascular, and inflammatory diseases. TT-00920 marks the companys second innovative drug candidate entering global clinical development.

---

LOCATION

Nanjing, , China

---

THERAPEUTIC AREAS

Cardiovascular Disease

Inflammatory Disease

Oncology

---

WEBSITE

https://www.transtherabio.com/en/

---

CAREER WEBSITE

https://www.transtherabio.com/en/job.aspx

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Feb 18, 2022

TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China

Nov 3, 2021

TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma

May 26, 2021

TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China

Dec 18, 2020

Teijin Pharma and TransThera Biosciences Form Strategic RandD Collaboration

Aug 17, 2020

LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions

For More Press Releases

---